NICE accepts golimumab for psoriatic arthritis

Up to 30% of people with psoriasis develop psoriatic arthritis
Up to 30% of people with psoriasis develop psoriatic arthritis

Golimumab (Simponi) has been recommended by NICE as an option in the treatment of psoriatic arthritis. It can be used in the same circumstances as the other tumour necrosis factor (TNF) inhibitor treatments (etanercept, infliximab and adalimumab) for this condition.

Specifically, golimumab may be used in adults with active and progressive psoriatic arthritis with 3 or more tender joints and 3 or more swollen joints when treatment with at least 2 DMARDs has failed. NICE has also stipulated that the manufacturer must provide the 100mg dose of golimumab for patients who weigh over 100kg at the same cost as the 50mg dose.

Treatment should normally be started with the least expensive TNF inhibitor, and should be stopped if response is not adequate at 12 weeks, as determined by the Psoriatic Arthritis Response Criteria (PsARC).

View Simponi drug record

Further Information: Merck Sharp & Dohme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in